Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258885 | 0.91 | ALDH1A1 (0.54) | RAB9AALDH1A1KMT2ATDP1L3MBTL1 | |
| SCHEMBL5048998 | 0.79 | RAB9A (0.38) | RAB9AALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL5050356 | 0.77 | RAB9A (0.41) | RAB9AALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL23812434 | 0.76 | ALDH1A1 (0.63) | RAB9AALDH1A1KMT2ATDP1L3MBTL1 | |
| SCHEMBL20710416 | 0.76 | MAPT (0.50) | RAB9AALDH1A1KMT2ALMNANPC1 | |
| SCHEMBL5050337 | 0.76 | MMP1 (0.38) | ALDH1A1TDP1CYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL20695025 | 0.75 | ALDH1A1 (0.57) | RAB9AALDH1A1KMT2ATDP1L3MBTL1 | |
| SCHEMBL28917944 | 0.75 | EGFR (0.40) | RAB9AALDH1A1TDP1NPSR1 | |
| SCHEMBL18868430 | 0.74 | KMT2A (0.71) | RAB9AALDH1A1KMT2AMEN1TDP1 | |
| SCHEMBL20710413 | 0.74 | MMP9 (0.47) | RAB9AALDH1A1KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | claimed |
| WO-2023154784-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4149549-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MacroGenics, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | MACROGENICS, INC. (US) | 2023-02-28 | — | — | US | claimed |
| WO-2021231309-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2021-06-10 | — | — | US | claimed |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | MACROGENICS, INC. (US) | 2021-03-30 | — | — | US | claimed |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. | 2019-05-02 | — | — | US | claimed |
| EP-3442574-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MacroGenics, Inc. (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017180813-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2017-10-19 | — | — | WO | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | MACROGENICS, INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023154784-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH A PD-1 X CTLA-4 BISPECIFIC MOLECULE | MACROGENICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | MACROGENICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | disclosed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272084-A1 | B7-H3 DIRECTED ANTIBODY DRUG CONJUGATES | CD274, CD2, CD22 | RAB9A 2561/4885ALDH1A1 1535/4885KMT2A 336/4885 |
| US-11591400-B2 | B7-H3 directed antibody drug conjugates | CD274, CD2, CD22 | RAB9A 2561/4885ALDH1A1 1535/4885KMT2A 336/4885 |
| US-10961311-B2 | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof | CD274, HRH3, CD2 | RAB9A 2460/4885ALDH1A1 1670/4885KMT2A 304/4885 |
| US-20190127471-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | RAB9A 2337/4885ALDH1A1 1647/4885KMT2A 327/4885 |
| US-20210171641-A1 | NOVEL B7-H3 BINDING MOLECULES, ANTIBODY DRUG CONJUGATES THEREOF AND METHODS OF USE THEREOF | CD274, CD2, CD22 | RAB9A 2337/4885ALDH1A1 1647/4885KMT2A 327/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | RAB9A 3528/4885ALDH1A1 450/4885KMT2A 774/4885 |
| US-20230226206-A1 | METHODS FOR THE USE OF A B7-H3 ANTIBODY-DRUG CONJUGATE ALONE OR IN COMBINATION | CD274, PDCD1, H1-3 | RAB9A 1819/4885ALDH1A1 382/4885KMT2A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.